Pharmacy sales in Ukraine for January-February 2025 rose by 8.3% in monetary terms compared to the same period in 2025—to more than 39.014 billion UAH, while in volume terms they decreased by 7.2%—to nearly 176,866 thousand packages, according to data from a study conducted by Business Credit and reported to the agency “Interfax-Ukraine.”
According to the data, the weighted average price of the pharmacy basket in January-February 2026 was 220.58 UAH per package, which is 16.67% higher than during the same period a year earlier.
At the same time, pharmacy sales of medicines during this period increased by 10.8% in monetary terms—to more than 31.396 billion UAH—and by 2.25% in volume terms compared to the same period in 2025, reaching 138 million packages.
The weighted average retail price of medicines for the first two months of 2026 was 227.5 UAH per package, which is 8.5% higher than in January–February 2025.
At the same time, pharmacy sales of dietary supplements in the first two months of 2026 increased by 12.46% in monetary terms, to nearly 4.6 billion UAH, while in volume terms they decreased by 17.3%, to 14.717 million packages. The weighted average price in this segment rose by 35.9% to 309.64 UAH per unit.
As reported, pharmacy sales in Ukraine for 2025 increased by 14.23% in monetary terms compared to 2024—to more than 220.287 billion UAH, while in volume terms they decreased by 2.25%—to nearly 1.135 million packages. The weighted average price of items in the pharmacy basket at the end of 2025 was 194.68 UAH per package, which is 16.86% higher than a year earlier.
At the same time, pharmacy sales of medicines during this period increased by 12.79% in monetary terms—to nearly 170.318 billion UAH—while in volume terms, they decreased by 0.2% compared to 2024, to 808.546 million packages.
The weighted average retail price of medicines at the end of 2025 was 210.65 UAH per package, which is 13% higher than at the end of 2024.
The pharmaceutical company “Farmak” remains the leader in retail sales in 2025 among domestic companies, with sales of nearly 10.978 billion UAH. The top 5 also included the pharmaceutical company “Darnitsa” (7.473 billion UAH), “Kyiv Vitamin Plant” (KVZ, nearly 6.842 billion UAH), ‘Arterium’ (5.975 billion UAH), and “Pharma Star/Acino” (2.9 billion UAH).
According to the results of a study conducted by Active Group and the Experts Club analytical center in February and presented at the Interfax-Ukraine press center, only 13.1% of respondents reported that they use the state drug reimbursement program, 70.6% do not use it, 16.3% had heard of it but did not use it.
“Low use of the program is often associated not with a lack of need, but with barriers to awareness and access,” said Experts Club founder Maxim Urakin.
“If people ‘have heard of it but have not used it,’ then the patient’s path to compensation remains difficult,” added Alexander Pozniy.
The survey was conducted on the SunFlowerSociology online panel on a representative sample on February 11-12, 2026.
The survey involved 1,000 respondents from a representative sample in all regions of Ukraine, except for the temporarily occupied territories.
ACTIVE GROUP, ALEXANDER POZNIY, EXPERTS CLUB, MAXIM URAKIN, MEDICINES, Reimbursement
The pharmaceutical company PrJSC Darnitsa (Kyiv) has registered a drug in Bosnia and Herzegovina for the treatment and prevention of neuromuscular transmission disorders, including myasthenia gravis, stimulation of the intestines and bladder after surgery, and restoration of muscle activity after anesthesia.
According to a press release from the company, the drug was registered at the end of December.
The registration certificate is valid for five years.
As previously reported, Darnitsa also registered an antifungal drug in Bosnia and Herzegovina.
Currently, Darnitsa’s drugs are available in more than 20 countries around the world.
Darnitsa has been operating on the market for over 90 years, is one of the ten largest pharmaceutical manufacturers in Ukraine, and produces 180 brands of drugs in 15 different forms. The strategic areas of portfolio development are cardiology, neurology, and pain management.
The net loss of PJSC “Pharmaceutical Firm ”Darnitsa“” (Kyiv) in January-June 2025 amounted to UAH 479.473 million, while in the same period of 2024, the company received a net profit of UAH 6.528 million. According to the Unified State Register of Legal Entities and Individual Entrepreneurs, the ultimate beneficiary of the company is Gleb Zagoriy.
The Verkhovna Rada, in its first reading, supported a bill that provides for changes to the 2025 state budget and an increase in funding for centralized procurement of medicines by 3.1 billion hryvnia.
According to the head of the parliamentary committee on health, medical care, and medical insurance, Mykhailo Radutsky, on Telegram, the additional funds are needed to purchase medicines for people with orphan diseases, viral hepatitis, HIV infection, tuberculosis, cancer, and other critical conditions.
Earlier it was reported that on July 1, the government supported a proposal to increase funding for the purchase of medicines from the state budget by UAH 3.1 billion, which is 36% of the additional need, while at the end of May, deputies registered in the Verkhovna Rada draft law No. 13308, which provides for the possibility of allocating additional funds for centralized medical purchases in the amount of UAH 8.624 billion from the reserve fund.
In total, the 2025 state budget provides for the allocation of UAH 11.8 billion for the purchase of medicines, while the Ministry of Health estimates that the need is UAH 19.8 billion. Thus, the planned funding covers only 59.4% of the need.
If funding is increased by UAH 3.1 billion, the need will be covered by 75%.
Ukraine plans to jointly manufacture lung and breast cancer drugs with Swiss pharmaceutical company Roche, Mykhailo Radutsky, chairman of the parliamentary committee on national health, medical care and medical insurance, said on his Facebook page, as part of the URC-2025 Ukraine Recovery Conference on Thursday.
“For several years, the President’s team has been negotiating with international pharmaceutical companies to localize production in Ukraine. The state enterprise “Medical Procurement of Ukraine” and Roche have signed an investment agreement to create capacities for the production of innovative drugs for lung and breast cancer in Ukraine,” he said.
Radutsky clarified that Roche will supply medicines in bulk, and their packaging, final packaging and labeling will be carried out directly in Ukraine, at the production facilities of the Ministry of Healthcare’s Medsnabzhenie branch.
He noted that in order to launch the project, it is necessary to obtain a GMP license for production and train staff.
Patients will be able to receive the first medicines under the project in 2027.
According to the State Enterprise (MoH), these are currently medicines for the two most common types of cancer – the drug for non-small cell lung cancer atezolizumab (Tecentrik) and pertuzumab + trastuzumab (Fesgo), which is used to treat breast cancer.
In January-May 2025, Ukraine imported medicines in dosage forms or packaged for retail trade for a total of $836.281 million.
According to the State Customs Service, exports of medicines during this period amounted to $92.989 million in monetary terms.
In addition, in the first five months of 2025, Ukraine imported non-dosed and non-packaged medicines for retail trade for $4.99 million, and ketgut, reagents, contrast agents, contraceptives and dental materials for $27 million.
The main countries from which Ukraine imports medicines are Germany (19.7%), India (10.4%) and France (7.36%). The main export markets are Uzbekistan (19.94%), Lithuania (19.7%) and Kazakhstan (13.4%).
